Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314580 | 0.98 | NAAA (0.39) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL4307907 | 0.95 | NAAA (0.39) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL4312944 | 0.93 | NAAA (0.38) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL4307836 | 0.91 | NAAA (0.40) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL9034880 | 0.91 | NAAA (0.30) | NAAA | |
| SCHEMBL1559459 | 0.89 | EPHX1 (0.42) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL8579936 | 0.89 | EPHX1 (0.42) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL5245472 | 0.87 | EPHX1 (0.39) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL9035280 | 0.83 | EPHX1 (0.35) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL451499 | 0.82 | NAAA (0.56) | NAAAEPHX1HTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3033078-A1 | ADJUVANTS IN ANTI-CANCER CHEMOTHERAPY | Jefford, Charles William (CH) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015022497-A1 | ADJUVANTS IN ANTI-CANCER CHEMOTHERAPY | JEFFORD CHARLES WILLIAM (CH) | 2015-02-19 | — | — | WO | disclosed |
| EP-2217564-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XenoPort, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-7514475-B2 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009033054-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
| EP-1919290-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI Biosciences, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1898951-A1 | PHARMACEUTICAL PREPARATION CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER | Daiichi Sankyo Company, Limited (JP) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007009087-A2 | METHODS AND PRODUCTS FOR TREATMENT OF DISEASES | DMI BIOSCIENCES, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007001067-A2 | SOLID DOSAGE FORM COMPRISING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007001065-A2 | METHOD FOR THE PREPARATION OF A WET GRANULATED DRUG PRODUCT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007001066-A1 | PHARMACEUTICAL PREPARATION CONTAINING AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076147-A1 | COMPLEX PANTOIC ACID ESTER NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | ADSL, SLC19A1, SLC25A21 | NAAA 171/4885EPHX1 3143/4885HTT 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.